GoTo Telemed, the nation's leading integrated telehealth ecosystem serving over 10 million patients nationwide, today announced the launch of its dedicated Rosacea Treatment Program, a comprehensive virtual care service designed to address the full spectrum of rosacea presentations through evidence-based diagnosis, personalized treatment planning, and ongoing management support. Delivered by a network of board-certified dermatologists and advanced practice providers, this program brings expert care to the estimated 5.5% of the global adult population affected by this chronic inflammatory condition .

Rosacea is a common, chronic inflammatory skin condition affecting primarily the central face, characterized by persistent redness, visible blood vessels, and inflammatory papules and pustules . A systematic review and meta-analysis published in the British Journal of Dermatology estimates the global prevalence of rosacea at approximately 5.46% of the adult population, with higher rates among women (5.41%) than men (3.90%) and peak prevalence between ages 45 and 60 years . Despite its prevalence and significant impact on quality of life, social functioning, and emotional well-being, access to dermatology expertise remains limited, with average wait times for in-person consultations exceeding three months in many markets .

"Rosacea is far more than a cosmetic concern—it is a chronic inflammatory condition that, when untreated, can significantly impair patients' quality of life, self-esteem, and social functioning," said a GoTo Telemed spokesperson. "Our Rosacea Treatment Program brings board-certified dermatology expertise directly to patients through telehealth, eliminating geographic barriers and long wait times. Whether a patient is experiencing persistent facial redness, inflammatory breakouts, or ocular symptoms, we provide accurate diagnosis, evidence-based treatment, and continuous support that helps them achieve lasting control over their condition."

Comprehensive Clinical Services for Rosacea Management

GoTo Telemed's Rosacea Treatment Program addresses the full spectrum of rosacea presentations through specialized clinical pathways aligned with current evidence-based guidelines, including the 2026 NICE Clinical Knowledge Summaries and American Academy of Dermatology recommendations :

Service Component Description and Clinical Applications
Comprehensive Diagnostic Evaluation Detailed clinical assessment to distinguish rosacea from acne, seborrheic dermatitis, lupus, and other facial dermatoses. Rosacea typically presents with persistent central facial erythema, flushing, papules and pustules without comedones, and telangiectasia . Updated guidance recognizes that signs and symptoms occur in varying combinations that can change over time, moving beyond the traditional four-subtype classification .
Personalized Treatment Planning Evidence-based treatment selection based on predominant phenotype, severity, and patient preferences, following stepwise NICE-aligned protocols: foundation of gentle skincare and trigger management; topical therapy for mild–moderate papulopustular disease; oral antibiotics for moderate–severe inflammatory involvement; and topical vasoconstrictors for persistent erythema when appropriate .
Trigger Identification and Avoidance Counseling Systematic assessment of individual triggers—including UV exposure, emotional stress, hot weather, wind, strenuous exercise, alcohol, spicy foods, hot beverages, and certain skincare products—with personalized guidance on avoidance strategies .
Gentle Skincare Education Evidence-based instruction on optimal skincare practices: gentle cleansing with pH-balanced synthetic detergents, lukewarm water, patting skin dry rather than rubbing; regular use of moisturizers containing barrier-repair ingredients (ceramides, niacinamide); and daily broad-spectrum sun protection with inorganic (mineral) sunscreens containing zinc oxide or titanium dioxide .
Ocular Rosacea Screening and Management Proactive assessment for ocular involvement—which can include dry eye, burning, stinging, photosensitivity, blurred vision, and conjunctival redness—with clear red flag guidance: eye pain, significant photophobia, reduced vision, or suspected keratitis requires urgent ophthalmology assessment .
Prescribing and Medication Management Electronic prescribing for topical agents (ivermectin, metronidazole, azelaic acid), topical vasoconstrictors (brimonidine), and oral antibiotics (doxycycline) with appropriate monitoring and safety counseling. Time-limited oral antibiotic courses are prescribed with a clear plan to step down to topical maintenance once controlled .
Laser and Light Therapy Coordination For patients with persistent telangiectasia or erythema inadequately responsive to medical therapy, coordination with affiliated centers for pulse dye laser (PDL), intense pulsed light (IPL), or 1064 nm Nd:YAG laser treatment, which are recognized as effective options for vascular manifestations .
Evidence-Based Diagnostic and Treatment Protocols

The program operates within a rigorous clinical framework aligned with NICE Clinical Knowledge Summaries, British National Formulary, and international dermatology guidelines :

Stepwise Treatment Approach: Following NICE-aligned protocols, clinicians initiate treatment based on disease phenotype and severity. For papulopustular rosacea, first-line options include topical ivermectin (often once daily), topical metronidazole, or azelaic acid. For moderate-to-severe inflammatory disease or inadequate response to topicals, oral tetracycline-class antibiotics (e.g., doxycycline) are prescribed in time-limited courses with a clear plan to step down to topical maintenance once controlled .

Persistent Erythema Management: For patients with prominent persistent facial erythema without significant inflammatory lesions, clinicians may consider topical vasoconstrictor options such as brimonidine where appropriate, carefully counseling patients about expected benefits and potential rebound phenomena .

Ocular Rosacea Protocol: Patients reporting eye symptoms receive systematic evaluation using validated screening questions. Simple "dry eye" symptoms can be part of rosacea and managed with artificial tears and warm compresses; however, eye pain, photophobia, reduced vision, marked redness, or suspected keratitis triggers immediate referral for ophthalmologic assessment .

Treatment Expectations and Adherence Counseling: Recognizing that poor adherence is a significant barrier to treatment success—real-world studies show only 40.6% of patients complete four consecutive weeks of treatment —clinicians provide structured counseling setting realistic expectations: improvement takes weeks, triggers matter, and many patients require maintenance topical therapy even after good response .

Addressing Diagnostic and Treatment Gaps in Rosacea Care

The Rosacea Treatment Program directly confronts persistent challenges in dermatologic care delivery:

Diagnostic Delays: Real-world studies document significant delays in rosacea diagnosis, with a median time from symptom onset to diagnosis of 10 months and some patients experiencing delays exceeding 24 months . During this period, patients suffer unnecessarily and may receive inappropriate treatments. GoTo Telemed's program provides rapid access to dermatology expertise, eliminating diagnostic delays.

Treatment Inappropriateness: Research reveals that 72.7% of patients with mild rosacea receive systemic antibiotics—often inappropriate for disease severity and contributing to antimicrobial resistance . Expert guidance ensures treatment is appropriately matched to disease phenotype and severity.

Adherence Challenges: Real-world data show only 40.6% of patients complete four consecutive weeks of treatment, with poor adherence undermining therapeutic outcomes . GoTo Telemed's structured follow-up and patient engagement tools support adherence and optimize outcomes.

Geographic Access Disparities: Dermatologist shortages in rural and underserved communities leave millions without access to specialized care. Telehealth eliminates geographic barriers, connecting patients with board-certified dermatologists regardless of location.

Underdiagnosis in Skin of Color: Rosacea in individuals with darker skin tones may not present with classic redness, leading to underdiagnosis and delayed treatment . GoTo Telemed's diverse provider network and emphasis on comprehensive phenotypic assessment improve recognition across all skin types.

Integration Within GoTo Telemed's Comprehensive Ecosystem

The Rosacea Treatment Program operates as a fully integrated component of GoTo Telemed's unified telehealth platform:

Unified Health Record: All consultation documentation, treatment plans, and follow-up assessments are incorporated into the patient's lifetime electronic health record, accessible to all authorized providers across medical and specialty care.

Seamless Care Coordination: When patients require in-person procedures such as laser therapy or skin biopsy, the platform facilitates warm handoffs to GoTo Telemed's network of affiliated dermatology centers and specialists.

Digital Imaging and Tracking Tools: Patients access validated tools for capturing and submitting standardized facial images through GoTo Telemed's secure patient portal and mobile application, enabling objective tracking of treatment response over time.

Prescribing and Pharmacy Integration: Prescriptions for topical and oral therapies are transmitted electronically to patient-selected pharmacies, with automated refill reminders supporting adherence.

Patient Education Resources: The platform provides access to a growing library of evidence-based educational materials on trigger avoidance, gentle skincare practices, and treatment expectations.

The Teledermatology Advantage for Rosacea Management

The rapid adoption of teledermatology platforms is transforming rosacea care delivery, with market research identifying this trend as a key driver of improved access and treatment uptake . GoTo Telemed's program leverages the unique advantages of virtual dermatology:

Visual Diagnosis Suitability: Rosacea's primarily visual manifestations make it particularly well-suited for telehealth evaluation, with high-quality patient-submitted images enabling accurate assessment of erythema, papules, pustules, and telangiectasia.

Convenience and Accessibility: Patients avoid the time, expense, and disruption of in-person visits, making it easier to seek timely care and maintain ongoing follow-up—critical for a chronic condition requiring long-term management.

Privacy and Comfort: Many patients feel self-conscious about facial redness and inflammatory lesions; virtual consultations from home reduce anxiety and increase willingness to seek care.

Continuity of Care: Regular virtual follow-up enables proactive management, early identification of flares, and timely treatment adjustments—preventing disease progression and improving long-term outcomes.

A Transformative Opportunity for Dermatology Providers

For board-certified dermatologists and advanced practice providers specializing in medical dermatology, GoTo Telemed's Rosacea Treatment Program offers a meaningful practice opportunity:

Focus on Meaningful Work: Providers dedicate their practice to a condition with profound impact on patients' quality of life and emotional well-being, experiencing the satisfaction of improving visible outcomes that matter deeply to patients.

Flexible Practice Model: Clinicians maintain complete autonomy over their schedules, practicing as little or as much as desired while serving a nationwide population of patients seeking rosacea expertise.

Complete Practice Support: GoTo Telemed provides full malpractice insurance coverage, comprehensive billing and coding support for dermatology services, and immediate access to a growing population of patients seeking rosacea management.

Professional Independence: Providers build their practice within GoTo Telemed's supportive ecosystem while maintaining clinical autonomy and professional decision-making authority.

No Administrative Burden: The platform handles all credentialing, scheduling, billing, and documentation, allowing clinicians to focus entirely on clinical care and patient relationships.

Regulatory Compliance and Quality Assurance

The Rosacea Treatment Program operates within GoTo Telemed's rigorous compliance framework:

State-Specific Licensure Management: Verification of active, unrestricted licenses in all states where care is delivered, with support for interstate licensure compacts

Dermatology Clinical Guidelines: Adherence to NICE CKS, American Academy of Dermatology, and international evidence-based guidelines for rosacea diagnosis and management

Quality Monitoring: Ongoing peer review, competency assessments, and patient outcome tracking ensuring maintenance of highest care standards

HIPAA-Compliant Infrastructure: Enterprise-grade encryption, access controls, and regular third-party security audits ensuring complete protection of patient health information

Availability and Partnerships

GoTo Telemed's Rosacea Treatment Program is available immediately to patients nationwide through the GoTo Telemed platform and mobile application. Patients may enroll directly or be referred by their primary care provider, or other health professional.

Board-certified dermatologists and advanced practice providers interested in joining GoTo Telemed's provider network are invited to apply through the company's credentialing portal.

GoTo Telemed is actively forming strategic partnerships with:

Dermatology practices seeking to expand virtual service offerings

Primary care networks managing dermatology conditions across large populations

Health plans and Medicare Advantage organizations

Employer wellness programs and employee assistance programs

Cosmetic and laser centers offering adjunctive procedural care


Media Contact:
GoTo Telemed Media Relations
[email protected]
(660) 628-1660
www.gototelemed.com